Israeli cornea treatment co EyeYon raises $25m
The Israeli company will use the capital to expand clinical trials to treat corneal endema.
Israeli medical device company EyeYon Medical EyeYon Medical today announced the completion of a $25 million Series C financing round, led by a global strategic leader in the ophthalmic industry and CR-CP Life Science Fund, together with Global Health Sciences (GHS) Fund (Quark Venture LP and GF Securities), BPC and existing investors Triventures, Rimonci, Pontifax and Diamond BioFund. The latest round brings the total amount of capital raised by the company to $36 million.
EyeYon Medical, which was founded in 2011 by Dr. Ofer Daphna, CEO Nahum Ferera, and Dr. Arie Marcovich, develops advanced technology to treat acute ophthalmic problems.
EyeYon Medical Raises $25 million in Series C to Transform Corneal Care
USA - English
News provided by
Share this article
Share this article
TEL AVIV, Israel, March 15, 2021 /PRNewswire/ EyeYon Medical announced today the completion of a $25 million in a Series C funding, led by a global strategic leader in the ophthalmic industry and CR-CP Life Science Fund. Other participants in the round include Global Health Sciences (GHS) Fund (Quark Venture LP and GF Securities), BPC and existing investors Triventures, Rimonci, Pontifax and Diamond BioFund.
EyeYon Medical was founded in 2011 by Dr. Ofer Daphna, CEO Nahum Ferera MD, and Dr. Arie Marcovich, MD., and develops advanced technology to treat acute problems in the ophthalmic world. The latest round brings the total amount of capital raised by the company to $36 million.